Showing 991-1000 of 1616 results for "".
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- MacuLogix Raises $38.7 Million in Series D Financing to Support Growthhttps://modernod.com/news/maculogix-raises-38-7-million-in-series-d-financing-led-by-vivo-capital/2479587/MacuLogix has completed a Series D round of financing totaling $38.7 million to further expand the MacuLogix team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx
- Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institutehttps://modernod.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/Glaukos announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide. Under the agreement, Glauko
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- HK Scientist Develops Retinal Scan Technology to Identify Early Childhood Autismhttps://modernod.com/news/hk-scientist-develops-retinal-scan-technology-to-identify-early-childhood-autism/2478987/A Hong Kong scientist has developed a method to use machine learning and artificial intelligence to scan retinas of children as young as six to detect early autism or the risk of autism and hopes to develop a commercial product this year, according to a Reuters
- Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russiahttps://modernod.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia. Terms of the deal were not disc
- Cultivating 4-D Tissues: The Self-Curving Corneahttps://modernod.com/news/cultivating-4-d-tissues-the-self-curving-cornea/2476176/Scientists at Newcastle University have developed a biological system which lets cells form a desired shape by moulding their surrounding material—in the first instance creating a self-curving cornea. In the research, a flat circle of gel containing corneal stromal cells (stem
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- EMA Endorses Macustar's Work on Early AMD Clinical Trialshttps://modernod.com/news/ema-endorses-macustars-work-on-early-amd-clinical-trials/2482631/The European Medicines Agency (EMA) has issued its third 'Letter of Support' to the Macustar consortium, a European public-private partnership focused on advancing clinical trial methodologies for early-stage age-related macular degeneration (AMD). This endorsement follows the consortium&